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Background and Purpose Abnormalities in visual perception are associated with a number of 
neurological diseases, particularly schizophrenia, and may represent a novel avenue of 
treatment for such disorders. However, translatability of pre-clinical models of psychosis to 
patient populations is lacking, particular with regards to the study of perception in these 
models. The purpose of the present study was to investigate the effect of pro-psychotic and 
schizophrenia-associated compounds on the ability of rats to perform a task of visual 
integration by proximity.  
Experimental Approach Rats were trained in a touchscreen operant environment to perform a 
visual discrimination between stimuli that were composed of rows of dots differing only in 
their relative horizontal and vertical proximity, a process thought to measure visual integration. 
Animals were then tested under the influence of glutamatergic (memantine, NVP-AAM077, CP-
101,606), serotonergic (psilocybin, ketanserin) and dopaminergic (D-amphetamine, 
methylphenidate, haloperidol) compounds while performing the visual discrimination task with 
a range of altered stimuli.  
Key Results The GluN2B-selective NMDA antagonist CP-101,606 impaired perceptual grouping 
on the task in a dose-dependent manner, while a GluN2A-selective antagonist showed 
increased ability on the task through a mechanism independent of grouping. Paradoxical 
results were encountered in agonist/antagonist drug pairings; the dopamine-releasing agent D-
amphetamine and the antipsychotic haloperidol both impaired perceptual grouping, whereas 
both agonist and antagonist at 5HT-2A, psilocybin and ketanserin, respectively increased 
accuracy, in a non-stimulus-specific manner, suggesting an underlying mechanism potentially 
distinct from perceptual grouping enhancement.  
Conclusions and Implications My findings add to the evidence that NMDA antagonists are 
strongly associated with alterations in visual cognition. They indicate GluN2B antagonism 
results in an impairment of visual grouping by proximity, whereas GluN2A antagonism 
increases task accuracy though in a non stimulus-specific manner. The findings also indicate 
potentially paradoxical interactions of monoaminergic pharmacology on visual perception, 





Mental illnesses and neurological diseases are most commonly understood in terms of the 
symptoms present when interacting with people and the world – for example, Alzheimer’s 
disease is associated with forgetfulness and wandering, while schizophrenia is associated with 
confused speech and delusions. However, the disruption of normal visual perception, which is 
also a feature of both of these disorders, is relatively unstudied. Visual perception deficits may 
contribute to higher-level symptoms; studies that focus on visual perception may lead to new 
ways to treat these and other disorders.  
In these studies, I used a task that may measure perceptual grouping. This is the ability to view 
objects with similar properties as associated with each other. This ability is disrupted in 
schizophrenia patients, but pre-clinical research is still lacking. Translatability between pre-
clinical animal models of disease and clinical human research is important to be able to 
extrapolate experimental findings to predictive outcomes in humans.  
My research focused on drugs associated with receptor systems thought to be disrupted in 
schizophrenia, and the effects of which produce schizophrenia-like symptoms: NMDA 
antagonists, serotonin-2A agonists, and dopamine-releasers. To quantify their effect on 
perceptual grouping, I trained rats to discriminate between rows of dots that were aligned 
either horizontally or vertically. The rats then performed the discrimination task under the 
influence of a variety of drugs, to see how each affected their ability to complete it. 
My investigation revealed that perceptual grouping deficits caused by NMDA antagonists may 
be localized to receptors containing the NR2B subunit. I also found grouping ability to be 
disrupted by the stimulant D-amphetamine and the antipsychotic haloperidol. The 5HT-2A 
agonist and antagonist psilocybin and ketanserin both increased accuracy on t task, the 








Vision is the primary sensory modality in humans. A disruption in visual perception would have 
significant effects on the way one can interact with the world, and may have knock-on effects 
on the wide array of cognitive mechanisms that rely on visual sensory input at some stage of 
their processing.  
Several neurological conditions have been demonstrated to express various visual perceptual 
deficits as part of their symptomology. These include Alzheimer’s disease (Cronin-Golomb 
1995; Holroyd & Shepherd 2001; Kirby et al. 2009) and autism-spectrum disorder (ASD) 
(Brosnan et al. 2004; Robertson et al. 2014). Perhaps the disorder most associated with 
dysfunction of visual perception is schizophrenia, which is partially characterized by visual and 
auditory hallucinations. In addition, schizophrenic populations seem to show an extremely high 
prevalence of deficits in perceptual organization - the ability to extract and resolve elements of 
a complex scene into distinct and identifiable objects (Kurylo et al. 2007; Silverstein & Keane 
2011; Uhlhaas & Silverstein 2005). The 
potential contribution of these impairments 
to the overall pathology of these diseases is 
surprisingly unexplored, considering that 
impairments in the ability to process 
information about external reality would, in 
theory, affect every cognitive process that 
relies on a form of sensory input. 
Investigating these impairments has been 
identified as a promising area for both 
clinical (Green et al. 2009) and pre-clinical 
(Siegel et al. 2013) research into 
schizophrenia. Perception may thus be a 
valid target for future treatment of the 
diseases I have mentioned, and may assist 
in understanding how disease pathology 
results in functional deficits. Furthermore, it 
Fig.1 – Hierarchal organisation of the visual cortex; feedforward 
projections propagate simple features upwards, where they 
conjugate onto neurones which are tuned to more complex features. 
Though in this example it is the resolution of a single object by 
contrast borders, the same principles apply to more abstract 




may be a useful biomarker to help diagnose neurological diseases in their early stages. For 
example it has been shown that deficits in early visual processing correlate with disease 
progression in Alzheimer’s patients (Uhlhaas et al. 2008).  
Deficits in perception arise when the basic function of the visual system, to transform an initial 
retinal input into distinct coherent images and scenes, is disrupted. Basic properties of visual 
information – shape, movement, colour, relative distance and spatial location, etc. – must be 
generated and processed from simple 2D inputs.  Visual integration is an ascending process 
through the visual cortex, whereby neurones in lower-level areas (V1) coding for simple 
features (ie. contrast, orientation) are integrated into neurones in higher areas (V2-V4) coding 
for larger and more complex features (see fig.1), which when finally resolved are considered 
distinctly salient objects (Caplovitz et al. 2008; Connor et al. 2007; Palmer et al. 2003; 
Wagemans et al. 2012). This process relies on competitive inhibition as ‘stronger’ visual 
elements are amplified and inhibit nearby neurones (Wyatte et al. 2012), with the visual cortex 
relying on an excitation/inhibition balance to maintain equilibrium and normal sensory 
processing (Marino et al. 2005). A major part of this perceptual organization is grouping, the 
process by which similar visual elements following particular principles are grouped together 
(see fig.2 for examples) to allow a visual scene to become more salient. It is these processes 
that are thought to be disturbed in neurological disorders which feature disrupted perceptual 
processes. For example, V2-V4 of the visual cortex has been demonstrated to have reduced 
activation when schizophrenic patients perform a perceptual integration task (Silverstein et al. 
2009). As well as upwards neural organisation, aspects of grouping also require recurrent top-
down connections, which can ‘label’ neurones that respond to features of the same object 
(Roelfsema & Houtkamp 2011; Sillito et al. 2006). The feedforward and feedback mechanisms 
of sensory processing I have described have some analogy to the bottom-up and top-down 
theories of psychosis, whereby hallucinations and delusions are theorised to occur either 
through unrestricted, unfiltered sensory input, or from over-compensated recurrent feedback 
that does not match with expected incoming signal (Corlett et al. 2009).  
 
The specific perceptual organisation principle that I will be investigating is grouping by 
proximity. This allows an easily-quantified scale of visual stimuli (see fig.3) – meaning that the 




trained to discriminate between 
rows of dots which were aligned 
either horizontally or vertically, 
with the perception of this 
alignment being dependent on the 
process of grouping. Once the 
animals had learned to 
discriminate between the two 
images, varying horizontal/vertical 
distance ratios were used; the 
most difficult stimuli to 
discriminate had a ratio close to 1, 
whereas the highest-signal image 
had a ratio of 2.76 (see fig.4). 
Stimuli were calculated to ascend 
in steps of 0.04 log10 [ratio]. 
Previous research has 
demonstrated that such a 
proximity grouping task is sensitive 
to pharmacological manipulation (Talpos 
et al. 2015b – please note that the 
memantine study therein was performed by myself, and relies on the same data as that 
presented in this thesis). 
The study of perceptual symptoms ameliorates some of the difficulties of modelling 
schizophrenia in animals. These are chiefly that there is a lack of convincing evidence that non-
primates suffer from identifiable mental illnesses, and the problem of studying a cognitive 
disorder in creatures much less cognitively developed than humans. Visuospatial disruptions 
can be more easily measured than, for example, thought disorganization or delusions. Despite 
this, little research has been conducted on perceptual measures in animal models. I have 
focused on pharmacological models over other mechanisms such as neonatal brain lesions and 
genetic modifications, which arguably show better validity in some measures (Lipska & 
Weinberger 2000), because of the ease and reversibility of acute drug administration allowed a 
Fig.2 – examples of classical grouping principles. Elements 
related by a particular factor are grouped together 




broader investigation than surgical or transgenic methods. Furthermore, pharmacological 
models can be directly tested clinically in humans for translational verification, something that 
is practically impossible with genetic or surgical studies. 
Observations that certain classes of drugs exacerbated symptoms of schizophrenia and induced 
psychotic-like symptoms in healthy subjects helped lead to the development of theories of the 
molecular biology of schizophrenia; NMDA antagonists (PCP and ketamine), dopamine 
releasing agents (amphetamine and cocaine), and 5HT-2A agonists (LSD). Drugs in these classes 
are often used as pharmacological tools in animal models of psychosis and schizophrenia 
(Marcotte et al. 2001; Lipska& Weinberger 2000).  
Similarities observed between both positive and negative symptoms of schizophrenia and the 
effects of NMDA antagonists such as ketamine and PCP (Javitt & Zukin 1991; Lahti et al. 1995) 
contributed to the development of the NMDA downregulation theory of schizophrenia (Olney 
& Farber 1995).  These drugs are now often used as pharmacological models of psychosis 
(Sams-Dodd 1996; Newcomer et al. 1999). In particular, chronic administration of NMDA 
antagonists can lead to long-lasting effects on cognition similar to those seen with 
schizophrenia, even after the drug has been eliminated from the body. A comprehensive 
overview of this and other associations of NMDA antagonists with cognition and schizophrenia 
are beyond the scope of this thesis - see Gilmour et al. 2012 for review.  
Previous research has demonstrated that ketamine can disrupt perceptual organization in both 
humans (Uhlhaas et al. 2007) and rats (Kurylo & Gazes 2008), with the disruption in humans 
mimicking deficits found in schizophrenic subjects (Silverstein et al. 2011). My work built on 
Talpos et al. 2015, where ketamine was shown to disrupt perceptual grouping by proximity, 
and MK801 and PCP to potentially impair performance on the task in a mechanism unrelated 
to grouping. I investigated memantine (used for treatment of Alzheimer’s disease), NVP-
AAM077 (partially selective for NR2A-subunit-containing NMDA receptors (Frizelle et al. 2006); 
more specific ligands unavailable), and CP-101,606 (selective for NR2B-subunit-containing 
NMDA receptors (Brimecombe et al. 1997)). The aim was to investigate whether inhibition of a 
specific subunit would result in the grouping deficit seen with ketamine in Talpos et al. 2015. 
Previous research has demonstrated pro-cognitive effects of NR2A and NR2B-selective 
antagonists (Gilmour et al. 2009; Dix et al. 2010; Smith et al. 2011). Furthermore, NR2A-




potentiation), and NR2B 
with LTD (long-term 
depression) (Liu et al. 
2004; Massey et al. 2004), 
with this modulation of 
plasticity potentially being 
involved with altered 
cognitive function. In 
addition, I was curious to 
see if a commonly-used 
therapeutic (memantine) 
exhibited effects on visual 
perception across a wide 
dose-range.  
The development of the serotonergic theory of schizophrenia lead from both the discovery of 
serotonin as a neurotransmitter, and the profound effect of the drug LSD on mood, thought, 
and sensory perception (Geyer & Vollenweider 2008 for review). Such 5HT-2A agonists induce 
phenomenological effects, such as ‘visual restructuralisation’ and ‘ego dissolution’ which are 
not dissimilar to those seen in schizophrenic patients (Gouzoulis-Mayfrank et al. 1998). The 
NMDA and 5HT-2A theories of schizophrenia overlap, with NMDA antagonists though to 
indirectly affect signalling properties of 5HT-2A/mGlu2 receptor complex-expressing pyramidal 
neurones which are necessary for the 
psychedelic and pro-psychotic effect of 
drugs such as LSD and psilocybin 
(Gonzalez-Maeso&Sealfon 2009; 
Gonzales-Maeso et al. 2008; Moreno 
et al. 2011). The amelioration of 
positive symptoms through 
antagonism of 5HT-2A is thought to 
contribute to the efficacy of atypical 
antipsychotic drugs (Horacek et al. 
Fig.4 – Table of ratios of the stimulus 
levels used. In ‘Horizontal’ stimuli, 
values were calculated with [a/b]; in 
‘Vertical’ stimuli, with [b/a]. 
Fig.3 – From left to right; examples of the hardest (0.01), medium (0.24), and easiest 
(0.44) stimuli pairs used (note that + was always centered in stimuli used, here may be 




2006), and a variety of serotonergic psychedelics have been used to model psychosis (Hanks & 
Gonzalez-Maeso 2012; Marona-Lewicka et al. 2011). Serotonergic projections have also been 
shown to innervate the visual cortex (Kosofky et al. 1984; Morrison et al. 1982) with the 5HT-
2A receptor to be found in high density in the region (Adams et  al. 2004) indicating a potential 
modulatory effect of the serotonergic system on perception.  
A prominent feature of serotonergic psychedelics are geometric hallucinations. It has been 
previously suggested that the cryoarchitecture of the visual cortex contributes to the nature of 
the geometric patterns characteristic of these drugs (Bressloff et al. 2002; Veltz et al. 2014). 
5HT-2A agonists, through a mechanism involving simulation of asynchronous glutamate 
release, may increase recurrent excitation and amplify feedback loops (Aghajanian & Marek 
1999). The overamplified processing of sensory information may be what leads to the visual 
hallucinations associated with 5HT-2A agonists. These same underlying processes are those 
necessary for perceptual organisation and ascending sensory information (Hupe et al. 1998; 
Shao and Burkhalter 1996). I thus hypothesised that disinhibited feedback loops in bottom-up 
sensory input caused by 5HT-2A agonists would likewise amplify grouping processes. To test 
the theory that 5HT-2A activation will increase grouping ability, I used the drugs psilocybin and 
ketanserin, respective agonists and antagonists at the receptor. Psilocybin has been used as an 
acute serotonergic model of psychosis (Geyer & Vollenweider 2008; Hanks & Gonzalez-Maeso 
2013), and in addition as a therapeutic for neuropsychiatric disorders such as alcohol 
dependence and depression (Tyls et al. 2013) which is why I chose to use it in my study over 
other commonly-used research tools such as DOI (Canal & Morgan 2012). 
The hyperdopaminergic theory of schizophrenia has been historically the most pervasive, 
having been tied to the development of classical antipsychotic drugs (see Davis et al. 1991 for 
review). Dopamine-releasing drugs such as amphetamine are associated with ‘stimulant 
psychosis’ at high doses (Curran et al. 2004), and have been used historically to model 
schizophrenia (Bell 1965; Snyder 1973), though recent analysis has questioned the validity of 
such methods (Lipska & Weinberger 2000). The hyperdopaminergic state is thought to result in 
aberrant assignment of salience, which leads to delusions when focused internally and 
perceptual disruptions when applied to sensory information (Kapur 2003). Thus I tested D-
amphetamine (the more active isomer of amphetamine), haloperidol, and methylphenidate. I 




organisation, the psychotomimetic D-amphetamine would impair grouping performance on 
the task.  
Haloperidol, an atypical antipsychotic, is a commonly prescribed drug to treat schizophrenia, 
and was thus selected to be tested for further investigation into the effects of therapeutic 
dopaminergic drugs on perception. In an ideal world, my hypothesis would have been that the 
drug has no effect on perception, or even produces an enhancement of grouping ability as a 
potential adjunct explanation for its efficacy as an antipsychotic; however, these drugs are 
known for their varied and diffuse cognitive impairments (an analysis of which is beyond the 
scope of this introduction), so conversely it would not have been surprising to produce a deficit 
in accuracy.  
Methylphenidate (commonly known as Ritalin), a drug with amphetamine-like effects but 
different mechanism of action (norepinephrine-dopamine reuptake inhibitor), was also 
investigated. Clinically, it is used for similar reasons to D-amphetamine; primarily ADHD, 
though similar profiles mean both can be used for disorders such as narcolepsy. Both drugs 
have shown similar cognitive effects on a variety of operant tasks (Mayorga et al. 2000).Though 
not as closely associated with psychosis as amphetamine, methylphenidate has been shown to 
exacerbate positive symptoms of schizophrenia, and has abuse potential that may lead to 
paranoia and other psychosis-associated side effects (Spensley & Rockwell 1972). 
The drugs I have mentioned are all associated, directly or indirectly, with the symptoms or 
treatment of schizophrenia and psychosis. Though the effect of such drugs (and others) on 
cognitive functions such as working memory and attention are relatively well studied, little pre-
clinical research on the way they modulate perceptual processing has been conducted 
(Carpenter & Koenig 2008; Dudchenko et al. 2013). It is for this reason that I investigated the 
effects of certain drugs associated with and used as models of psychosis on perceptual 




To analyse the accuracy data produced in this experiment, I utilised mixed effects logistic 
regression models. These can analyse significance of interaction (where the shape of the curves 
is changed, to imply intersection) and main effect (where the curve is shifted in parallel) 
between treatment and visual stimuli. An interaction between dose and stimuli would imply a 
specific effect of drug on perceptual grouping, whereas a main effect implies an effect on visual 


















Fig.5– Graph displaying mean accuracy of group of animals (n = 22) learning to 




Materials and Methods 
Subjects 
All animals were treated in accordance with the European Ethics Committee (decree 
86/609/CEE), the Animal Welfare Act (7 USC 2131) and the Guidelines for the Care and Use of 
Mammals in Neuroscience and Behavioural Research (National Research Council 2003). The 
study protocol was approved by the local animal experimental ethical committee at Janssen 
Research &Development (Beerse, Belgium). 
Male Lister-hooded rats (Harlan, Netherlands, 200-240g on arrival) were used for the studies. 
These were divided into two groups of 24 – rats in the first group (PG1) were approximately 12 
months old at start, whereas rats in the second group (PG2) were ordered at the beginning of 
the study. Drug tests were performed on only one of these groups. All animals were group 
housed (4 rats each) in individually-ventilated cages (approx. 48cm L x 37cm W x 22cm H; 
temperature maintained at 22°C, humidity 55%) on a 12 hour normal light/dark cycle. Animals 
were provided with in-cage enrichment consisting of red plastic tunnels and chew blocks.  Each 
rat was fed approximately 15g of food per day (Purina standard rat chow) to maintain them at 













Treatment Mean Latencies (log10 (ms) Trials 75% 
(mg/kg) Response SE Collection SE Completed SE Stimuli 
Memantine               
VEH 3.403 0.017 3.123 0.015 95.455 0.376 0.108 
0.3 3.397 0.017 3.106 0.014 95.591 0.409 0.121 
1 3.382 0.017 *3.094 0.013 94.864 0.893 0.121 
3 3.451 0.024 #3.099 0.016 93.318 1.894 0.120 
10 ***4.062 0.040 ***3.300 0.020 ***48.954 4.325 0.270 
        
NVP-AAM077               
VEH 3.400 0.014376 3.132 0.010 103.682 0.274 0.171 
5 3.438 0.011953 3.143 0.021 103.818 0.125 0.206 
10 ***3.598 0.040362 ***3.181 0.013 *94.409 4.176 0.113 
20 ***3.857 0.050393 ***3.229 0.018 ***62.682 7.028 0.141 
        
CP-101,606               
VEH 3.422 0.011 3.136 0.009 104.000 0.000 0.140 
1 3.406 0.015 *3.114 0.009 104.000 0.000 0.143 
3 *3.386 0.013 ***3.097 0.011 104.000 0.000 0.177 
10 #3.395 0.014 ***3.078 0.010 103.909 0.063 0.244 
        
D-Amphetamine               
VEH 3.433 0.016 3.122 0.016 99.105 1.661 0.118 
0.25 ***3.351 0.021 3.106 0.016 98.105 2.586 0.136 
0.5 ***3.328 0.021 3.146 0.038 90.421 6.515 0.178 
0.75 ***3.355 0.021 3.144 0.019 **75.211 7.325 0.197 
        
Methylphenidate               
VEH 3.428 0.020 3.105 0.015 103.684 0.316 0.126 
1 3.427 0.017 3.107 0.014 103.684 0.316 0.127 
3 #3.396 0.019 3.101 0.017 104.000 0.000 0.132 
10 ***3.367 0.018 3.107 0.021 102.053 1.339 0.168 
        
Haloperidol               
VEH 3.455 0.018 3.115 0.015 103.263 0.737 0.113 
0.01 3.502 0.023 3.128 0.018 102.263 1.629 0.129 
0.02 ***3.615 0.026 ***3.174 0.019 *98.368 2.177 0.125 
0.04 ***3.808 0.036 ***3.247 0.022 ***67.368 6.400 0.161 
        
Psilocybin               
VEH 3.400 0.013 3.162 0.038 95.286 4.144 0.130 
0.3 #3.476 0.019 3.199 0.033 89.381 5.430 0.119 
1 ***3.623 0.025 3.240 0.024 *77.905 4.633 0.081 
3 ***3.881 0.044 ***3.338 0.040 ***40.810 4.921 0.072 
        
Ketanserin               
VEH 3.442 0.015 3.152 0.011 104.000 0.000 0.165 
0.3 3.468 0.018 3.165 0.011 103.727 0.230 0.125 
1 3.464 0.018 3.165 0.008 103.773 0.197 0.135 
3 3.473 0.017 *3.174 0.009 103.364 0.444 0.112 
 
Fig.6 – Effects of compounds on secondary measures (for visual representation, see fig.7 and 8). The presence of an asterisk indicates 






All work was performed using modified Med Associates operant chambers (Med Associates 
Inc., Fairfax, Vermont; 33.5 cm H × 32.5 cm W × 40 cm L).One side of the chamber was 
equipped with a tone generator, a house light, and a food pellet receptacle (containing a 
reward light and an infra-red nose-poke detector) connected to a pellet dispenser. The 
opposite wall was replaced with a touch-sensitive infrared system paired with a computer 
monitor (26cm H x 36cm W). This monitor was partially covered with a metal ‘mask’ with two 
windows, restricting response to the areas upon the screen where images would appear. To 
slow the response of tested animals, and thus facilitate training and accuracy (Bussey et al. 
2008), a counterweighted steel flap (5cm x 36cm) was placed in front of the screen. All operant 
chambers were housed within sound-attenuated boxes (60cm x 74cm x 60cm), fitted with a 
small ventilation fan. Screens and operant box functions were controlled by K-limbic software 
(K Limbic, Sawbridgeworth, UK).   
 
Compounds 
Compounds were administered either via subcutaneous (D-Amphetamine, haloperidol, 
methylphenidate, ketanserin, CP-101,606) or intraperitoneal (memantine, psilocybin, NVP-
AAM077) injection in physiological saline solution (with the exception of CP-101,606, which 
was dissolved in 10% lactate + 5% glucose) at volumes of 1ml/kg for s.c. and 10ml/kg for i.p. 
route. Administration regimens (administration time and dose) were based on historical data 
and published accounts in other operant tasks. Memantine, D-Amphetamine –administered 60 
minutes prior to start of task; haloperidol, psilocybin, ketanserin, CP-101,606, NVP-AAM077- 
30 minutes; methylphenidate - 20 minutes. Each compound was tested using a within-subject 
design, with all subjects receiving all doses of each compound, based on a randomized latin 
square design. Drugs were administered on Tuesdays and Fridays, to allow several days for 
washout between tests, in a window between 13:00 and 15:00 when possible. Memantine was 
administered at 0.3, 1.0, 3.0, 10.0 mg/kg (Talpos et al. 2012) , D-Amphetamine at 0.25, 0.50, 
0.75 mg/kg (Talpos et al. 2014), Psilocybin at 0.3, 1.0, 3.0 mg/kg, Haloperidol at 0.01, 0.02, 0.04 
mg/kg (Talpos et al. 2015a), Methylphenidate at 1, 3, 10 mg/kg (Robinson 2012), Ketanserin at 




et al. 2015). Compounds were sourced from Sequoia Research Products (memantine, NVP-
AAM077, CP-101,606), THC Pharm (psilocybin), Certa S.A. (D-amphetamine), or synthesised 
internally (ketanserin, methylphenidate, and haloperidol). 
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Fig.8 – Effect of compounds on number of trials completed (maximum = 104, except 






Rats were initially acclimatized to the operant chambers by placing them inside while the fans 
were running for approximately 45 minutes. A peanut butter and reward pellet (45mg, 
sucrose-based) mixture was placed on the screen, steel flap, and mask, in order to facilitate 
exploration of screen area. This was necessary to encourage interaction with the screen for 
future task acquisition. Once animals had acclimatized –determined by having consumed all 
peanut butter across various screen locations - they were moved onto tone training. This 
entailed a reward pellet being released into the pellet receptacle in conjunction with the 
sounding of the reward tone and the activation of the pellet receptacle light. Once the pellet 
was collected (detected by an infrared beam within the magazine), the light would turn off, 
and after 10s another pellet would be delivered with tone and light activation. This was done in 
order to train animals to associate sounding of the tone and the illumination of the food 
magazine with the delivery of a pellet. The session ended after the delivery of 60 pellets or 
after 45 minutes had passed, whichever came first. Animals proceeded to the next stage of 
training once they had completed 60 trials for two consecutive sessions.  
The next stage of pre-training involved the rats learning to associate touching the screen with 
the delivery of a food reward. Initially, three large white boxes (covering most of the screen) 
were displayed. Touching any part of any of these images resulted in the images being 
removed from the screen, the reward tone sounding and a food pellet being dispensed. Once 
the pellet was collected, a 5-second ‘inter-trial-interval’ (ITI) occurred, and the next trial was 
initiated. As in previous pre-training, animals moved onto the next stage of training once they 
had achieved 60 completed trials on two consecutive sessions.  
The final pre-training phase was similar to the previous one, except only one of the three white 
boxes on the screen was displayed, with the location changing randomly after each trial. This 
was done to ensure that rats learned to respond to presented stimuli, and not a particular 
spatial location on the screen. Once again animals were required to complete 60 trials within 








This task consisted of a visual discrimination (discussed in detail later) in which subjects were 
required choose one of two stimuli to earn a food pellet. The stimuli consisted of dot lattices, 
which weremore strongly aligned either horizontally or vertically. This is defined by the ratio of 
distance between horizontal and vertical dots. At lower ratios, the alignment is weaker and the 
stimuli are harder to discriminate. The stimuli were expressed as Log10[ratio] (see fig.4), 
ascending in regular steps from 0.01(hardest) to 0.44 (easiest). One ‘very easy’ stimuli with a  
ratio of 5.9 (0.77 in log10 units) was also included as part of the task following its use in the 
perceptual grouping protocol of Kurylo & Gazes 2008, though it was omitted from further 
statistical analysis and curve-fitting on learning that inclusion would skew results toward this 
‘high-influence point’.  
 
Perceptual Grouping Task Training 
Rats were initially trained on stimuli with the penultimate greatest ratio (0.44), in order to 
acquire either a horizontal or vertical preference. Half of the rats were trained to select 
horizontal, and half vertical. Stimulus pairs were displayed in the two windows of the mask, 
with location randomized across trials within a session. On selection of the correct stimulus, 
rats were rewarded with a foot pellet. If the incorrect stimulus was selected, all lights were 
extinguished for 10s, before the image was re-displayed and trial repeated until the correct 
stimulus was selected. These repeated ‘correction trials’ did not count towards the total 
number of trials completed, nor were they included in accuracy measurements and analysis. To 
reach criterion in this stage of training (and to proceed to the next stage), animals had to 
complete a minimum of 72 trials within 45 minutes, as well as an average of at least 80% trials 
correct over 3 days. This was achieved in all animals over a period of 15 sessions (see fig.5 for 
mean acquisition of PG2 group). 
The final stage of training was to ensure they could perform the discrimination task with the 
modified, more perceptually-ambiguous stimuli. During the session, all 12 levels of difficulty 
were presented 8 times in a randomized order (96 total trials), with a session lasting for 45 




least five sessions of training before being moved onto drug testing, to ensure that rats were 
able to complete the task with stable performance and a stimuli-dependent accuracy. This final 
training was identical to the protocol used during pharmacological testing. 
 
Statistics 
Operant boxes were controlled, and raw data generated, via K-Limbic (Conclusive Solutions, 
Sawbridge, UK) and then further formatted with Microsoft Excel 2010. Secondary measures - 
number of trials completed, and response & food pellet collection latencies were analysed with 
Statistica (Version 10; StatsSoft).  Accuracy across levels 0.01 – 0.44 was investigated using R. 
To test for effects of drug treatments on latencies (response and collection), all data were 
transformed into log10 (latency (ms)). This was to ensure that means were not skewed by 
excessively large latencies (where, for example, an animal had simply got distracted for a long 
time). Repeated measures ANOVA, with a post hoc analysis of Dunnett’s T-test against vehicle, 
were performed.  
The number of completed trials were analysed with T-test – this was done as, in some tests, 
there was not enough variance to perform ANOVA’s.  
For analysis of accuracy (% correct), a mixed effects logistic regression model was utilized. This 
approach was based on four-parameter logistic regression models used in bio-assays. The 
advantages of this model over an ANOVA are that it is more powerful and accounts for the 
variance structure of percentage-based data. Furthermore, it allows the clear ascending 
hierarchy (0.01 having the lowest expected outcome, and 0.44 having the highest) to be 
considered. This allowed both the ‘main effect’ (if there was an overall increase/decrease in 
accuracy across all levels), and ‘interactive effect’ (whether there was an interaction between 
stimulus level and dose, ie. if the curves were non-parallel) of treatment to be analysed. 
Though the 0.77 ratio was included in test suites, it was omitted from further analysis due to it 
acting as a high-influence point and skewing the X-axis. Due to the complexity of this statistical 
approach, it was conducted by an external statistician. Details of the advantages of this 
approach are detailed in (Zhao et al. 2001), and a more in-depth description of the model can 
















Fig.9 – Effects of drugs on task accuracy. Tables highlight presence of significant effects of ‘main 
effects’ (ME) and ‘interactive effects’ (Int.) between compounds and stimulus. Effects of compounds on 
accuracy at 0.01 and 0.44 (minimum and maximum) ratios are also highlighted. Vertical lines represent 






No effect was observed on either main effects or interactions between memantine treatment 
and difficulty, except with the 10mg/kg condition (p<0.01 for both). Significant differences 
from vehicle were also found at the 0.01 (p<0.01) and 0.44 (p<0.001) stimulus level (see fig.9a). 
The significant effects on secondary measures were similarly restricted to the 10mg/kg 
condition, reducing trials completed by almost 50% (p<0.001), and increasing mean response 
time to over 10 seconds (p<0.001). A highly significant increase in collection latency was found 
at 10mg/kg (p<0.001), and a small but significant decrease at 1mg/kg (p<0.05) (see fig.6). 
 
NVP-AAM077 
Administration of NVP-AAM077 did not result in any interactive effects. However, significance 
was observed in the main effect, in a U-shaped dose-response; 5 mg/kg decreased accuracy 
(p<0.05), whereas 10 mg/kg (p<0.001) and 20 mg/kg (n.s.) increased it. This dose-response was 
also evident in contrasts at 0.01 and 0.44 levels, with 10 mg/kg the only dose reaching 
significance (p<0.05) (see fig.9b).  
The effect of treatment on secondary measures followed a much more linear pattern. Both 
response and collection latencies were increased at 10 and 20 mg/kg (p<0.001). Number of 




CP-101,606 treatment resulted in a significant main effect of treatment only at 1mg/kg 
(p<0.05) (despite this dose causing very little shift in the ratio at which 75% accuracy was 
achieved), but highly significant (p<0.001 for all) interactions of level and dose were found. This 




1mg/kg dose was the only one that presented significance (p<0.05)), and highly significant 
decreased accuracy at the 0.44 level (p<0.001 for all treatments) (see fig.9c). 
No effect was observed on number of trials completed. However, CP-101 significantly 
decreased response latency at the 3mg/kg treatment (p<0.05), and collection latency at all 
treatments (p<0.001 for 3mg/kg and 10mg/kg, p<0.01 for 1mg/kg) against vehicle (see fig.6). 
 
Psilocybin 
Psilocybin administration resulted in an overall increase in accuracy, with the main effect 
reaching significance at the 1 mg/kg and 3 mg/kg doses (p<0.01) (see fig.9g). No interactive 
significance was observed, though the difference in accuracy was more prominent at the 0.01 
‘hard’ level than the 0.44 ‘easy’ level (p<0.1 for 1 mg/kg and 3 mg/kg).  
Latencies were visibly increased on a dose-dependent scale, reaching significance for response 
latencies at the 1 mg/kg and 3 mg/kg doses (p<0.001) and at the 3 mg/kg dose for collection 
latencies (p<0.001) (see fig.7). Trials completed were likewise impaired at the 1 mg/kg dose 
(p<0.05), and by over 50% at 3 mg/kg (p<0.001) (see fig.8). 
 
Ketanserin 
Significant main effects, signifying an overall increase in accuracy, were observed at all doses of 
ketanserin (p<0.01, p<0.05, p<0.001 respectively with ascending dose). The level at which 75% 
accuracy is achieved can thus be seen to shift downwards – though it should be noted that for 
the vehicle condition, the ratio is visibly higher than in other experiments (above 0.16, whereas 
vehicle in other tests stayed between 0.12 and 0.16, see fig.9h). No significance was observed 
in regard to interactive effects.  
Secondary measures were mostly unaffected by ketanserin treatment; the exception being 







D-Amphetamine had no main effect of treatment on accuracy (though produced a visible shift 
in the level at which 75% accuracy was obtained, see fig.9d), but a significant interaction of 
level and dose was found at 0.50 mg/kg (p<0.05) and 0.75 mg/kg (p<0.01) doses. There was no 
significant difference in accuracy at the 0.01 level, though significant decreases in accuracy 
were observed at the 0.44 level with all treatments (p<0.05, p<0.01, p<0.001 for 0.25, 0.50 and 
0.75 mg/kg respectively) (see fig.9d). 
Trials completed decreased as dose increased, though this was only significant at the 0.75 
mg/kg treatment (p<0.01).  Collection latencies were mostly unaltered, with no treatment 
reaching significance, though the slight decrease in response latencies was highly significant at 
all doses (p<0.001) (see fig.6). 
 
Methylphenidate 
Methylphenidate had minimal effects on accuracy, with no significant interactive effects at any 
dose. A parallel decrease in accuracy was found at the highest dose (p<0.01), however (see 
fig.9e). 
Trials completed and collection latencies were unaffected, but response latencies decreased 
slightly with dose, reaching significance at the 10 mg/kg treatment (p<0.001) (see fig.6). 
 
Haloperidol 
Treatment with haloperidol presented no significant main effects at any dose, but had 
interactive effects at the 0.01 mg/kg (p<0.01) and the 0.04 mg/kg (p<0.05) doses. These results 
are reflected in the effects on accuracy at the 0.44 level, with significant decreases occurring at 
0.01 mg/kg (p<0.01) and 0.04mg /kg (p<0.001), and near-significant at 0.02 mg/kg (p<0.1). At 
the 0.01 level, slight increases in accuracy are seen at all but the highest dose, though this does 




Haloperidol significantly increased both collection and response latencies at 0.02 and 0.04 
mg/kg (p<0.001) (see fig.7). Likewise, the number of trials completed decreased as dose 











Fig.10 – Accuracy on the PG task of different groups of animals. Animals in Rat1 (PG1) were 
approximately 10 months older than animals in Rat2 (PG2). Data was acquired through one 
session for rats, and two sessions for mice (due to halved number of trials per session for 
mouse group). No significance was found at any level between any group using a repeated-







Three NMDA antagonists were tested: memantine, NVP-AAM077 (NR2A-selective) and CP-
101,606 (NR2B-selective).  
Memantine, a therapeutic agent commonly used in the treatment of Alzheimer’s disease, was 
the first drug tested, as effects may have had relevance for human patient populations. At 
most doses tested memantine had negligible effects on both accuracy and secondary 
measures. However, the highest dose was an exception; compared to other doses, subjects 
completed half the number of trials with mean response latency increased to over 10 seconds, 
suggesting severe non-specific cognitive impairments. Unusually, significance was observed 
with both main effect and interactions at the maximum dose, and significant contrasts at both 
the easiest and hardest levels. These broad-range impairments make it difficult to determine if 
the interactive significance indicating a grouping deficit is biologically relevant or merely an 
artefact of non-specific cognitive impairment. While a comparison of human and rat 
pharmacokinetics is beyond the scope of this thesis, the maximum recommended daily dose of 
memantine in humans is 20mg p.o., compared to the 10mg/kg used in this study; the lack of 
effects at all but the highest dose suggests that perceptual effects are unlikely to occur at 
therapeutic doses. 
The NR2A-partially-selective compound NVP-AAM077 and the NR2B-selective compound CP-
101,606 were tested to investigate the potential pharmacodynamic cause of the differential 
effects on perception revealed by the Talpos’ study. No research has previously investigated 
the effects of subunit-selective compounds on perceptual organization; however various 
differential effects on cognition have been demonstrated (Brigman et al. 2013; Kumar et al. 
2015). Though too broad to summarise here, results seemed to show that antagonism of 
specific subunits resulted in pro-cognitive effects in some tasks, and deficits in others. In 
particular, antagonism at GluN2B showed improved performance on a number of tasks 
(Gilmour et al. 2009; Dix et al. 2010; Smith et al. 2011). I therefore expected differential effects 
of NR2A and NR2B antagonism on grouping, with binding at one particular subunit resulting in 




2013; Talpos et al. 2015b), and the other having no effect on grouping to match results seen 
with other NMDA antagonists (Talpos et al. 2015b). 
No significant effect on interaction was found with the NR2A antagonist NVP-AAM077, 
indicating no effect on grouping due to lack of stimuli-specificity, though a U-shaped dose-
response was observed on overall accuracy. 5mg/kg treatment resulted in a significant 
decrease in task accuracy, while 10 mg/kg resulted in significant increases in accuracy; 
meanwhile 20 mg/kg showed no significant change. This unusual response, restricted to the 
main effect, is not dissimilar to the results seen with MK801 and PCP in Talpos et al. 2015b. 
However, the linear effect of dose on latencies and trials completed indicates a psychomotor 
alteration more similar to ketamine than MK801 and PCP. It has been previously demonstrated 
that PCP and MK801 have a small effect on visual discrimination ability (Talpos et al. 2012), and 
little or no effect on perceptual grouping (Talpos et al. 2015b). However, both NVP-AAM077 
and CP-101,606 have previously been demonstrated to have no effect on visual discrimination 
ability (Talpos et al. 2009), and thus the enhancement seen with NVP-AAM077 may represent 
modulation of a cognitive mechanism that is distinct from both perceptual grouping and 
discrimination. 
CP-101,606 resulted in significant interactive effects at all doses. There is a visible increase in 
accuracy at low-ratio conditions and impairment at ‘easier’ stimuli at all doses; though the 
overall effect tends towards impairment as the dose increases, there is an increase in accuracy 
at the lower signal levels at all doses. The notable absence of effects on secondary measures 
indicates a lack of non-selective cognitive and motor impairments (though latencies decreased 
slightly at higher doses, indicating a slight psychomotor disinhibition), which may be associated 
with the lack of NR2B expression in the cerebellum (Wang et al 1995). This result is very similar 
to that seen with ketamine in Talpos et al. 2015b, which was also determined to impair 
grouping while having little or no visuospatial disruption (Talpos et al. 2009, Talpos et al. 2014), 
indicating NR2B in the mechanism by which ketamine produced the disruption.  
It seems likely from these results that blocking NR2B-containing NMDA receptors produces a 
specific impairment of perceptual grouping, whereas antagonism of NR2A-containing NMDA 
receptors results in a non-specific enhancement of visual perception distinct from both 
grouping and discrimination. However, other NMDA antagonists such as ketamine, MK801, PCP 




Neyton 2007). One confounding factor may be NVP-AAM077’s lack of specificity – though 
selective for the NR2A subunit, it also does have affinity for NR2B (Neyton & Paoletti 2006) as 
well as NR2C and NR2D –containing receptors (Feng et al. 2004 – note that NVP is referred to 
as PEAQX).The mechanisms of antagonism also vary; ketamine, MK801 and PCP act as channel 
blockers, NVP-AAM077 acts as a competitive antagonist, and CP-101,606 as a negative 
allosteric modulator. These different mechanisms of antagonism may affect the way in which 
perception is affected. Electrophysiological studies using NVP-AAM077 and CP-101,606 have 
indicated that LTP is primarily dependent on the NR2A receptor and LTD on the NR2B receptor 
(Liu et al. 2004; Massey et al. 2004).  Though much research on synaptic plasticity has been 
conducted in the visual cortex, the differential effects of LTP and LTD on visual cognition are 
little investigated. My research indicates that the effects (and absence thereof) on perceptual 
grouping by NR2A and NR2B selective drugs could be associated with differential effects on LTP 
and LTD, as well as net excitation and inhibition (Talpos et al. 2015b).  
CP-101,606‘s clear disruption of perceptual grouping ability indicates that it is potentially a 
better pharmacological model for the perceptual effects of psychosis than the more commonly 
used MK801 and PCP, which previous research has shown to have minimal effect on perceptual 
organisation (Talpos et al. 2015b). The lack of psychomotor impairment may also mean it is 
superior to ketamine; one potential avenue of research would be to investigate and compare 
the effects of [sub-]chronic dosing regimens which are used in pharmacological models of 
schizophrenia (Becker et al. 2006; Goetghebeur & Dias 2008). Other investigations should focus 
on translatability factors, such as comparing results to see if the deficit is similar to that 
expressed by schizophrenic patients, and testing the drug in human measures of perception. 
 
5HT-2A receptor ligands 
Two 5HT-2A receptor ligands were tested: psilocybin and ketanserin. 
With psilocybin, I predicted an increased accuracy on the task, and was partially correct; it did 
indeed increase in a dose-dependent manner with psilocybin administration. This was 
particularly interesting at the easiest difficulties, where an increase of 5% to 95% accuracy 
represented half of the maximum possible increase before the 100% ceiling. This increase in 




greater than other consecutive doses. However as the statistical significance was restricted to a 
main effect, it cannot be inferred that the increase in task accuracy was the result of a specific 
improvement in grouping ability. In much the same way that a non-selective decrease in 
accuracy would imply a generalised cognitive impairment, the parallel increase in grouping 
accuracy seen with psilocybin administration may be the result of a non-selective cognitive 
enhancement. One possible explanation would be that the motor impairment that lead to an 
increase in latencies also allowed more time to process the stimuli, in much the same way that 
slowing response by adding a flap to touch has been shown to increase accuracy on operant 
tasks (Bussey et al. 2008). It may also be that psilocybin enhances visual discrimination ability 
through a mechanism that is not specific to grouping.  
A study of ketanserin, a 5HT-2A antagonist, followed. This drug has been previously 
demonstrated to attenuate both visual disturbances and ‘Altered State of Consciousness rating 
scale’ scores induced by psilocybin (Vollenweider et al. 1998). Thus, I expected psilocybin and 
ketanserin test outcomes to be opposing. As can be seen in fig.9g+h, this was not the case. 
Instead, ketanserin dose-dependently increased accuracy as a main effect with no significance 
on interaction, similar to the results seen with psilocybin.  Other than the S-shaped 
dose/response (0.3 mg/kg showed a greater effect on accuracy than 1.0 mg/kg), the effect of 
the drugs on task performance were remarkably similar. 
Without further investigation, it is difficult to speculate on a pharmacodynamic mechanism 
that would result in such non-opposing effects of antagonistic drugs. Rigorous 
counterbalancing and test day spacing should have averted the possibility of rebound and 
withdrawal effects, and unlike psilocybin ketanserin showed almost no effect on latencies, so 
increased accuracy cannot be as a result of it allowing more time to process the visual signal. 
One potential pharmacodynamic explanation may be the drugs non-selective nature; psilocin 
(the active metabolite of psilocybin) binds the 5HT-1A receptor (Passie et al. 2002). 
Additionally, psilocin’s partial agonism at 5HT-2A may have disrupted some sort of intrinsic 
activity at the receptor in a way similar to ketanserin’s antagonism. Psilocin has been 
demonstrated to modulate concentrations of 5HT and dopamine in various cortical areas 
(Sakashita et al. 2015), and psychedelic serotonergic drugs have been shown to require 
interactions with mGlu2/3 (Gonzalez-Maeso et al. 2008; Moreno et al. 2011) and CB1 (Mato et 




2004), so it is possible that the disrupted processes which lead to altered task performance are 
not even localized to the visual cortex – one must infer that perceptual effects mediated by 
5HT-2A ligands through cognitive assays, rather than imaging studies. 
It may be fallacious to expect linear on/off dynamics correlating with pharmacology; any 
movement from the optimal equilibrium can be considered aberrant, with upwards or 
downwards direction equally representing a disruption. The 5HT-2A ligands I have tested may 
be disrupting glutamatergic signalling, and in such complex dynamic balances as those 
encountered in the sensory system even small aberrations in the excitation/inhibition balance 
may have unpredictable effects (Vreeswijk & Sompolinsky 1996). Further investigations into 
the exact role and nature of the 5HT-2A receptor and its effect on visual cognition are 
warranted. In particular, verification of the effects on visual discrimination on a protocol such 
as that in Talpos et al. 2011 may elucidate my study results.  
 
Dopaminergics 
Three dopaminergic drugs were tested: D-amphetamine, methylphenidate, and haloperidol. 
D-amphetamine dose-dependently caused a significant interactive impairment in accuracy, in 
absence of a main effect. The impairment was most prominent on easy stimuli, with the lowest 
dose actually slightly increasing accuracy at the hardest level. D-amphetamine also decreased 
response latencies (in line with its profile as a psychomotor stimulant)  which may have 
amplified impairment on the task due to decreased attention and processing time; however, 
previous research on amphetamines effect on attention-based tasks have actually 
demonstrated an increase in accuracy accompanied by decreased response times (Bizarro et al. 
2004). This suggests that perceptual grouping is specifically affected by the drug, which is in 
line with the prediction that a pro-psychotic drug such as D-amphetamine would impair 
perceptual abilities similar to the impaired visual organisation expressed in schizophrenia. 
Due to the relatively non-selective pharmacodynamic mechanisms of D-amphetamine (which 
to summarise, lead to increased synaptic dopamine and norepinephrine concentrations) it is 
difficult to say which (if any) specific receptor and pathway is associated with this alteration in 




amphetamine specifically thought to mimic over-expressed top-down processing (Corlett et al. 
2009); it is possible that pathways in areas such as the prefrontal cortex may contribute to 
perceptual abnormalities via D1-mediated backprojections (Noudoost & Moore 2011). 
Furthermore, dopamine has been demonstrated to modulate retinal function (Witkovsky 
2004), leading to the possibility that alterations in visual function may not even be constrained 
cortically. Similar to the dopaminergic system, norepinephrine pathways project widely 
throughout the brain, including into the visual cortex (Pourtois et al., 2012; Markovic et al. 
2014), and the neurotransmitter is associated with neuroplasticity (Brocher et al. 1992). 
Though these backprojections are most closely associated with emotional salience and arousal 
(Bradley et al. 2003), their potential influence in an affectively-neutral task such as the one I 
have been investigating cannot entirely be disregarded. These distributed and often vague 
effects associated with D-amphetamine make it difficult to pinpoint a particular mechanism 
that would lead to impairment in perceptual grouping. Nevertheless, this confirmation that a 
specific perceptual deficit is elicited by a drug that has long been associated with psychosis 
should prove as a useful reference.  
The next drug to be tested was methylphenidate. Its effect on perceptual grouping was mostly 
benign; no interactive effects were seen with any treatment, though an impairment in the form 
of a main effect was found at the highest dose. Likewise significant effects on response latency 
were found only at the highest dose. This lack of effect on perception, and the lack of 
precipitated psychomotor effects at all but the highest dose confirm that despite similar 
properties to D-amphetamine, methylphenidate has a lower propensity for psychotic and 
schizophrenia-associated perceptual effects. 
Haloperidol revealed an unusual profile of effects on perceptual abilities. The effects on 
accuracy followed a U-shaped dose-response curve; interactive effects were found at the 0.01 
and 0.04 mg/kg doses, but not at 0.02 mg/kg. This was also evident in the 0.44 contrasts, with 
0.01 and 0.04 but not 0.02 mg/kg showing significant differences. This non-linear response may 
be due to the mixed pharmacological profile of haloperidol; of which the primary mechanisms 
of action are thought to be based on D2 and 5HT-2A receptor antagonism. Though non-
significant, a small increase in accuracy was observed at the harder levels with the lower doses 
of haloperidol, supporting the suggestion of my previous investigations of psilocybin and 




visible similarity between D-amphetamine and haloperidol – though the drugs are not 
pharmacological opposites, their effects with regard to psychosis can be considered opposing. 
These paradoxical results lead to the potentially troubling implication that observations of 
perceptual deficits in schizophrenic patients may be confounded by antipsychotic medication. 
Though previous research into perceptual deficits in schizophrenics has indicated no effect of 
medication dose on task performance (as reviewed in Silverstein & Keane 2011), this finding of 
antipsychotic-induced perceptual impairment n healthy animals may yet indicate an 





















Aberrant perceptual organisation ability is a key characteristic of schizophrenia, and it must be 
considered when designing animal models of the disease. Having demonstrated that grouping 
is disrupted by D-amphetamine, haloperidol, and CP-101,606 on my protocol, the next step 
would be to create an analogous proximity grouping task for humans. If it can be demonstrated 
that schizophrenia patients display similar deficits to those induced by the drugs I have tested, 
the translatable validity of my findings would be greatly increased. 
With regards to further pre-clinical research, there are several key areas that may be explored. 
These are primarily related to the paradoxical findings found with the pharmacologically 
opposing drugs psilocybin and ketanserin, and the therapeutically opposing drugs D-
amphetamine and haloperidol. Testing the 5HT-2A drugs on a visual discrimination task would 
clarify whether increased task accuracy was due to an enhancement of such ability, or if it was 
the result of disruption of another process in the visual sensory pathway. Similarly, the effects 
on accuracy caused by NVP-AAM077 could not be due to either grouping or visual 
discrimination ability (Talpos et al. 2009), so further research is necessary to fully understand 
the cognitive profile of this drug. Further pharmacological studies targeting both 5HT-2A and 
D1/D2 receptors should also shed light on the reasons for such unexpected similar effects on 
grouping as were encountered with D-amphetamine and haloperidol. The paradoxical result 
found with these drugs is of particular relevance for clinical studies of perceptual deficits in 
schizophrenic populations, as they may represent a potential confound in patients medicated 
with atypical antipsychotics such as haloperidol. 
One theory could be that pharmacodynamic interactions with a specific receptor are less 
important than the equilibrium of intrinsic activity and excitation/inhibition balance that is 
being disrupted by a foreign ligand binding. Optimal sensory processing in the visual cortex 
relies on maintaining an excitation/inhibition balance in order for relevant visual elements to 
be further processed and for irrelevant noise to be filtered out (Wyatte et al. 2012), and has 
been theorised to be directly involved with the process of grouping (Talpos et al. 2015b).  
Whereas glutamatergic drugs such as NVP-AAM077 and CP-101,606 may disrupt this directly, it 
is possible that drugs binding the 5HT-2A receptor are indirectly modulating this equilibrium 




decrease may be less relevant than one might assume, as either direction represents 
impairment relative to the ‘normal’ level of performance. Indeed, it may be that such 
seemingly paradoxical results are a feature, rather than an anomalous artefact, of disrupting 
particular aspects of visual processing pharmacologically. Further experimentation is required 
to take this speculation any further. The cholinergic and cannabinoid systems are two areas 
unexplored in this study, and have drugs which are associated with psychosis-like effects (for 
example, THC (Semple et al. 2005) and scopolamine (Cairncross 1983)) that may be 
investigated with this task to test this hypothesis. 
Much previous research has demonstrated that sensory processing in the visual cortex is 
dependent on both bottom-up and top-down pathways (Grossberg & Williamson 2001; Hupe 
et al. 1998; Rauss et al. 2011; Kastner et al. 2001; Petro et al. 2014; Palmer et al. 2003; 
Roelfsema & Houtkamp 2011; McMains & Kastner 2010; McMains & Kastner 2011). Both 
directions are involved in maintaining the excitation/inhibition balance in the visual cortex 
which I have previously discussed (Shao and Burkhalter 1996; Zhang et al. 2014). Perceptual 
abnormalities encountered in schizophrenia are likewise classified as either bottom-up or top-
down aberrations (Aleman et al. 2003; Corlett et al. 2009). My research and results do not 
differentiate the processes causing the increase or decrease of accuracy on the grouping task; 
accuracy changes may be related to decreased relative noise through enhanced contrast in 
competitive interactions in the visual cortex, or an enhanced signal through top-down 
amplification of early neural coding, or a number of other possibilities. Though some research 
has experimentally investigated the effects of top-down modulation on visual processing 
(McAlonan et al. 2008; Bradley et al. 2003; Noudoost & Moore 2011), specific pharmacological 
interactions are largely uninvestigated. Future investigations may try to connect theorised 
affinities of specific drugs to bottom-up/top-down processes to measureable effects on visual 
processing. 
Though not covered in this thesis, I have also shown that mice can learn to complete the 
grouping task with performance analogous to that of rats (see fig.10). This opens the door to 
research into transgenic models of disease and perception, with particular relevance to autism-
spectrum disorders and Alzheimer’s disease. 
Finally, one new direction of research that may contribute to understanding the mechanisms of 




throughout my investigation that this protocol tests “grouping”, and that grouping occurs as an 
ascending process through the visual cortex, there is yet to be any definitive research to 
confirm this. Accordingly this work would benefit from research to prove the construct validity 
of this task, as well as the grouping phenomena in the rodent. A potential method to do this 
would entail a c-fos study to investigate the difference in selective activation of of the visual 
cortex between, for example, a perceptual grouping and a standard visual discrimination task 
(which is assumed not to require the visual cortex). Even more detailed work may involve 
single-cell recording within the visual cortex to investigate at which precise layer proximity 
grouping occurs, and whether it is the same for all levels of difficulty. 
My study has focussed on clinically-relevant drugs, many of which have complex and non-
selective effects. Further investigation into the specific neuropharmacological mechanisms of 
grouping may require a more targeted approach, such as agonists that target the 
norepinephrine and dopamine receptors specific to subtype, as well as reuptake inhibitors and 
other modulators. In particular, a more selective pharmacological approach may help in 
verifying the cause of the paradoxically-similar outcomes seen with D-amphetamine and 
haloperidol. I hope I have shown that proximity grouping is a valid mechanism to evaluate 
perceptual disruption in the rodent, and that that individual drugs have patterns of disruption 
that can be assayed on this protocol. Future work should elaborate this through pharmacology 
in both rodent and human to increase translatability and predictive validity, as well as to 
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